IRVING, Texas, Jan. 11 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc., today announced they have launched a new corporate website. The redesigned website is located at Carrington’s current URL of http://www.carringtonlabs.com and contains new features such as site search functionality, improved navigation, and updated information on Carrington’s products and services. New pages have also been added containing information on Carrington’s subsidiaries and other markets such as veterinary and oral care products. The online shopping cart has also been redesigned to make it much easier to purchase Carrington’s products via the web.
DelSite Biotechnologies, Inc., Carrington’s drug delivery subsidiary, has more visibility and information related to its development of a nasal powder vaccine using its GelVac(TM) formula with the H5N1 (bird flu) antigen. Potential partners now have several points to access the DelSite website, http://www.delsite.com . Links are available throughout the site including, a prominent logo located on the bottom right hand side of the homepage, through the drug delivery sections under Markets We Serve and Research, and through the Subsidiaries page.
“Over the past six months, Carrington has been analyzing our market presence and strategy of all our business segments and brands. One consistent theme that continued to come up from potential customers and partners was our website,” stated Mr. Doug Golwas, Vice President of Corporate Sales and Marketing. “It did not accurately reflect our company’s image and contained little information on who we are and what we do. The new website has addressed these concerns and portrays Carrington as what it is, a research- oriented, global supplier of health products.”
In conjunction to launching the redesigned website, Carrington will be implementing an Internet marketing campaign to build awareness of its brands and services. The Internet marketing campaign will consist of search engine optimization, pay-per-click advertisements, banner advertisements with industry organizations, an email marketing initiative and an online customer retention program. By combining the Internet marketing campaign with the new website, Carrington hopes to reach out to a larger group of customers and improve communication with existing customers and partners.
About DelSite
Carrington’s wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from the Department of Health and Human Services. In September of 2006, DelSite entered into a three-year CRADA with the Laboratory of Cellular Oncology at the National Cancer Institute (NCI) to determine if GelVac(TM) nasal powder delivery platform is adaptable for delivering human papillomavirus virus-like particles (HPV VLP) vaccines in a powder dosage form for mucosal immunization.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.
Carrington Laboratories, Inc.
CONTACT: Doug Golwas, VP, Corp. Sales & Mktg of Carrington Laboratories,Inc., +1-972-518-1300
